Loading
FUBP1 (Far upstream element-binding protein 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Colorectal cancer and 2 more.
Regulates MYC expression by binding to a single-stranded far-upstream element (FUSE) upstream of the MYC promoter. May act both as activator and repressor of transcription.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.72 (direct and indirect evidence; datatypes literature 0.98, genetic association 0.54, somatic mutation 0.77). IntOGen calls it a driver in 4 cohorts (2 activating, 2 loss-of-function), covering Invasive Breast Carcinoma, Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Low-Grade Glioma, NOS.
In plain words · FUBP1 (Far upstream element-binding protein 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Colorectal cancer and 2 more.
FUBP1 (Far upstream element-binding protein 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Colorectal cancer and 2 more.
Regulates MYC expression by binding to a single-stranded far-upstream element (FUSE) upstream of the MYC promoter. May act both as activator and repressor of transcription.
No product in this corpus aims at FUBP1 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA FUBP1: RNA low tissue specificity; high antibody staining in 45 normal tissues; highest cancer staining breast cancer (11 of 11 high). Distribution: 5 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Skin cancer (all types), Breast cancer (all types), Colorectal cancer, Lung cancer (all types), Leukaemia); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q96AE4; CIViC gene FUBP1; IntOGen FUBP1; Human Protein Atlas FUBP1 tissue; Open Targets ENSG00000162613 associations
First described 1994. Earliest sequence paper UniProt cites for the protein: Duncan et al, Genes Dev, 1994, "A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif". Source.
Sources: HGNC HGNC:4004 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q96AE4 (protein name, function text, keywords and locations (REST API)); CIViC gene FUBP1 (1 evidence items, 0 assertions, 1 variants; diseases: Oligodendroglioma (GraphQL API, CC0)); Open Targets ENSG00000162613 (association with cancer (MONDO_0004992) 0.72; per-cancer scores at or above 0.5: colorectal cancer 0.54, skin cancer 0.61, lung cancer 0.50 (GraphQL API, CC0)); IntOGen FUBP1 (driver in 4 cohorts (Act 2, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Regulates MYC expression by binding to a single-stranded far-upstream element (FUSE) upstream of the MYC promoter. May act both as activator and repressor of transcription. Location: Nucleus (UniProt). Locus 1p31.1 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"FUBP1" OR ABSTRACT:"FUBP1" OR TITLE:"far upstream element binding protein 1" OR ABSTRACT:"far upstream element binding protein 1" OR TITLE:"Far upstream element-binding protein 1" OR ABSTRACT:"Far upstream element-binding protein 1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FUBP1, not a curated reading list.